Loading
Life sciences · Journal article
Journal of Basic and Clinical Physiology and Pharmacology · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve cardiovascular (CV) outcomes in type 2 diabetes mellitus, and several agents benefit patients without diabetes, yet their mechanisms remain incompletely understood. This narrative review examines whether these benefits arise from direct cardiac actions, systemic hemodynamic and metabolic effects, or both. We performed a structured PubMed search for CV outcome trials, mediation analyses, human mechanistic and imaging studies, and preclinical studies, classifying each proposed mechanism by its supporting evidence. Outcome trials consistently show that SGLT2 inhibitors reduce heart failure (HF) hospitalization and slow kidney disease progression, whereas GLP-1 RAs reduce atherosclerotic events, but these trials cannot identify the responsible mechanisms. Human data support contributions from natriuresis, decongestion, and renal hemodynamics for SGLT2 inhibitors and from glycemic, vascular, and anti-inflammatory effects for GLP-1 RAs, although mediation analyses explain only part of either class's benefit. Direct myocardial actions remain largely hypothetical in humans. The CV effects of both classes are best viewed as overlapping, interacting hemodynamic, renal, metabolic, vascular, and neurohormonal mechanisms rather than a direct-versus-systemic dichotomy. Clinically, the evidence supports prioritizing SGLT2 inhibitors for HF and chronic kidney disease and GLP-1 RAs for atherosclerotic CV disease and obesity-related risk.